Latest Breaking News On - Family zhang - Page 1 : comparemela.com

Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaHong kongJay meiAsia pacificPrnewswire antengene corporation limitedUniversity of texas md anderson cancer centerAntengene corporation limitedAmerican association for cancer research annual meetingCorporation limitedCancer centerFamily zhangChief medicalAmerican associationCancer research annual meetingPatients beyond

Antengene Presents Encouraging Clinical Data From Four Pipeline Programs At The 2023 R&D Day

Antengene Presents Encouraging Clinical Data From Four Pipeline Programs At The 2023 R&D Day
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Hong kongSouth koreaJay meiPeter qianAsia pacificCompany annualHong kong stock exchangeAntengene corporation limitedMd anderson cancer centerAntengene corporationAntengene shanghai officeCorporation limitedFamily zhangChief medical officerCancer centerPatients beyond

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to.

South koreaHong kongPeter qianJay meiAsia pacificAntengene corporation limitedCompany annualAntengene corporationMd anderson cancer centerAntengene shanghai officeHong kong stock exchangeFamily zhangChief medicalCancer centerCorporation limitedPatients beyond

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to.

United statesSouth koreaHong kongJay meiPeter qianAsia pacificHong kong stock exchangeAntengene corporationAntengene corporation limitedPrnewswire antengene corporation limitedCompany annualUniversity of texas md anderson cancer centerAmerican association for cancer research annual meetingCorporation limitedInstitutional review boardCancer center

Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop, commercialize, and manufacture.

South koreaHong kongUnited statesPeter qianBristol myers squibbJay meiAsia pacificAntengene corporation limitedSociety for immunotherapyPrnewswire antengene corporation limitedHong kong stock exchangeCompany annualAntengene corporationCorporation limitedFamily zhangChief medical